S&P 500   4,668.31 (+1.60%)
DOW   35,236.11 (+0.96%)
QQQ   399.48 (+2.12%)
AAPL   160.66 (+2.46%)
MSFT   337.51 (+2.38%)
FB   338.44 (+1.60%)
GOOGL   2,902.95 (+2.08%)
AMZN   3,580.94 (+2.18%)
TSLA   1,133.89 (+4.80%)
NVDA   330.26 (+4.83%)
BABA   131.94 (-1.06%)
NIO   40.13 (+0.35%)
CGC   11.16 (-4.53%)
AMD   159.34 (+2.93%)
GE   98.04 (+0.20%)
MU   85.07 (+1.98%)
T   23.98 (-0.99%)
F   19.83 (+0.41%)
DIS   145.92 (-1.48%)
ACB   6.52 (-3.98%)
AMC   36.67 (-2.55%)
PFE   53.85 (-0.28%)
BA   197.81 (-0.70%)
S&P 500   4,668.31 (+1.60%)
DOW   35,236.11 (+0.96%)
QQQ   399.48 (+2.12%)
AAPL   160.66 (+2.46%)
MSFT   337.51 (+2.38%)
FB   338.44 (+1.60%)
GOOGL   2,902.95 (+2.08%)
AMZN   3,580.94 (+2.18%)
TSLA   1,133.89 (+4.80%)
NVDA   330.26 (+4.83%)
BABA   131.94 (-1.06%)
NIO   40.13 (+0.35%)
CGC   11.16 (-4.53%)
AMD   159.34 (+2.93%)
GE   98.04 (+0.20%)
MU   85.07 (+1.98%)
T   23.98 (-0.99%)
F   19.83 (+0.41%)
DIS   145.92 (-1.48%)
ACB   6.52 (-3.98%)
AMC   36.67 (-2.55%)
PFE   53.85 (-0.28%)
BA   197.81 (-0.70%)
S&P 500   4,668.31 (+1.60%)
DOW   35,236.11 (+0.96%)
QQQ   399.48 (+2.12%)
AAPL   160.66 (+2.46%)
MSFT   337.51 (+2.38%)
FB   338.44 (+1.60%)
GOOGL   2,902.95 (+2.08%)
AMZN   3,580.94 (+2.18%)
TSLA   1,133.89 (+4.80%)
NVDA   330.26 (+4.83%)
BABA   131.94 (-1.06%)
NIO   40.13 (+0.35%)
CGC   11.16 (-4.53%)
AMD   159.34 (+2.93%)
GE   98.04 (+0.20%)
MU   85.07 (+1.98%)
T   23.98 (-0.99%)
F   19.83 (+0.41%)
DIS   145.92 (-1.48%)
ACB   6.52 (-3.98%)
AMC   36.67 (-2.55%)
PFE   53.85 (-0.28%)
BA   197.81 (-0.70%)
S&P 500   4,668.31 (+1.60%)
DOW   35,236.11 (+0.96%)
QQQ   399.48 (+2.12%)
AAPL   160.66 (+2.46%)
MSFT   337.51 (+2.38%)
FB   338.44 (+1.60%)
GOOGL   2,902.95 (+2.08%)
AMZN   3,580.94 (+2.18%)
TSLA   1,133.89 (+4.80%)
NVDA   330.26 (+4.83%)
BABA   131.94 (-1.06%)
NIO   40.13 (+0.35%)
CGC   11.16 (-4.53%)
AMD   159.34 (+2.93%)
GE   98.04 (+0.20%)
MU   85.07 (+1.98%)
T   23.98 (-0.99%)
F   19.83 (+0.41%)
DIS   145.92 (-1.48%)
ACB   6.52 (-3.98%)
AMC   36.67 (-2.55%)
PFE   53.85 (-0.28%)
BA   197.81 (-0.70%)
NASDAQ:ENTA

Enanta Pharmaceuticals Stock Forecast, Price & News

$85.84
-6.05 (-6.58%)
(As of 11/29/2021 12:21 PM ET)
Add
Compare
Today's Range
$83.19
$91.54
50-Day Range
$54.10
$97.37
52-Week Range
$40.32
$102.00
Volume
9,889 shs
Average Volume
153,333 shs
Market Capitalization
$1.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.64
30 days | 90 days | 365 days | Advanced Chart
Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Enanta Pharmaceuticals logo

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Headlines

Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Raised to $73.00
November 24, 2021 |  americanbankingnews.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Gap Up to $75.18
November 23, 2021 |  americanbankingnews.com
Enanta Pharmaceuticals's Earnings: A Preview
November 19, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTA
Employees
141
Year Founded
N/A

Sales & Book Value

Annual Sales
$97.07 million
Book Value
$19.76 per share

Profitability

Net Income
$-36.17 million
Pretax Margin
-110.82%

Debt

Price-To-Earnings

Miscellaneous

Free Float
17,842,000
Market Cap
$1.74 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/22/2021
Today
11/29/2021
Next Earnings (Estimated)
2/14/2022
Fiscal Year End
9/30/2022

MarketRank

Overall MarketRank

2.07 out of 5 stars

Medical Sector

520th out of 1,392 stocks

Pharmaceutical Preparations Industry

243rd out of 670 stocks

Analyst Opinion: 2.3Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

Is Enanta Pharmaceuticals a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Enanta Pharmaceuticals stock.
View analyst ratings for Enanta Pharmaceuticals
or view top-rated stocks.

How has Enanta Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ENTA stock has increased by 61.2% and is now trading at $85.32.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Enanta Pharmaceuticals?

Enanta Pharmaceuticals saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 681,000 shares, a decrease of 36.9% from the October 31st total of 1,080,000 shares. Based on an average daily trading volume, of 168,400 shares, the short-interest ratio is presently 4.0 days. Currently, 3.8% of the shares of the stock are sold short.
View Enanta Pharmaceuticals' Short Interest
.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, February 14th 2022.
View our earnings forecast for Enanta Pharmaceuticals
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its quarterly earnings data on Monday, November, 22nd. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.31) by $0.09. The biotechnology company had revenue of $23.58 million for the quarter, compared to the consensus estimate of $35.65 million. Enanta Pharmaceuticals had a negative net margin of 81.38% and a negative trailing twelve-month return on equity of 18.53%. During the same quarter last year, the firm earned ($0.55) EPS.
View Enanta Pharmaceuticals' earnings history
.

What price target have analysts set for ENTA?

8 analysts have issued 12 month target prices for Enanta Pharmaceuticals' shares. Their forecasts range from $55.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $90.88 in the next year. This suggests a possible upside of 6.5% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the following people:
  • Jay R. Luly, President, Chief Executive Officer & Director
  • Paul J. Mellett, CFO & Senior VP-Finance & Administration
  • Yat Sun Or, CSO, Senior Vice President-Research & Development
  • Nathalie Adda, Chief Medical Officer & Senior Vice President (LinkedIn Profile)
  • Nathaniel S. Gardiner, Secretary, Senior Vice President & General Counsel

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.78%), First Manhattan Co. (4.80%), Krensavage Asset Management LLC (4.63%), Renaissance Technologies LLC (3.74%), Dimensional Fund Advisors LP (3.02%) and Geode Capital Management LLC (1.65%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda and Paul J Mellett.
View institutional ownership trends for Enanta Pharmaceuticals
.

Which major investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Millennium Management LLC, BlackRock Inc., Tudor Investment Corp Et Al, Renaissance Technologies LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, and South Dakota Investment Council. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda, and Paul J Mellett.
View insider buying and selling activity for Enanta Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Enanta Pharmaceuticals stock?

ENTA stock was bought by a variety of institutional investors in the last quarter, including First Manhattan Co., Assenagon Asset Management S.A., Portland Global Advisors LLC, UBS Group AG, TD Asset Management Inc., Citadel Advisors LLC, Voloridge Investment Management LLC, and Barclays PLC.
View insider buying and selling activity for Enanta Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $85.32.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals has a market capitalization of $1.72 billion and generates $97.07 million in revenue each year. The biotechnology company earns $-36.17 million in net income (profit) each year or ($3.91) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

Enanta Pharmaceuticals employs 141 workers across the globe.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is www.enanta.com.

Where are Enanta Pharmaceuticals' headquarters?

Enanta Pharmaceuticals is headquartered at 500 ARSENAL STREET, WATERTOWN MA, 02472.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at (617) 607-0800, via email at [email protected], or via fax at 617-607-0530.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.